Zafirlukast pocket delivery impairs the capsule healing around textured implants in rats.
BACKGROUND
The aim of this study was to investigate the effects of zafirlukast on capsule thickness, collagen fiber density, and myofibroblast cell count of the healing tissue around silicone textured implants in rats.


METHODS
Thirty-six male Wistar rats were divided (n = 18) into two groups. In one group, two parallel incisions (1.5 cm long) were made into the right and left sides of the spine. Two pockets were then created in which shell-shaped textured implants were inserted. The left-side pocket was injected with 0.2 ml of saline solution (SSG) and the right-side pocket with a dose of 1.25 mg/kg of zafirlukast (ZLG). The other 18 rats (sham, SG) had only one pocket created, followed by the placement of an implant and injection of 0.2 ml of saline solution. The rats were euthanized on the 7th, 35th, or 90th days followed by careful dissection of the implant. The capsules and peri-implant tissues were prepared for histologic analysis. An ANOVA test and Tukey test were applied (p < 0.05).


RESULTS
ZL was effective in impairing the capsule thickness on the 35th and 90th days compared to the other two groups (sham and saline). Not only was it effective in impairing the collagen density on the 35th and 90th days, but it also showed the same effect in the SSG (systemic); fewer myofibroblasts were counted on the 90th day in the ZLG compared to the SG group; the number of myofibroblasts was significantly lower in the ZLG than in the SSG.


CONCLUSIONS
Pocket delivery of one dose of Zafirlukast was effective in impairing capsule formation around the textured implant.
Moreira
Marcio
M
Plastic Surgery Brazilian Society (SBCP), Maringa, PR, Brazil, plasticlinic@brturbo.com.br.
Fagundes
Djalma José
DJ
de Jesus Simões
Manuel
M
de Oliveira
Mônica Cristina Baiardi Mizoguti
MC
Dos Santos Previdelli
Isolde Terezinha
IT
Moreira
Amanda Castilho
AC
D000704:Analysis of Variance; D000818:Animals; D018427:Breast Implants; D002452:Cell Count; D003094:Collagen / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D005347:Fibroblasts / Q000187:drug effects* / Q000473:pathology; D007150:Immunohistochemistry; D007211:Indoles; D020024:Leukotriene Antagonists / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D048448:Phenylcarbamates; D011474:Prosthesis Design; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D020034:Silicone Gels; D013449:Sulfonamides; D013997:Time Factors; D014105:Tosyl Compounds / Q000009:adverse effects* / Q000494:pharmacology; D014945:Wound Healing / Q000187:drug effects*
D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D020034:Silicone Gels; D013449:Sulfonamides; D014105:Tosyl Compounds; D003094:Collagen; C062735:zafirlukast